Tim Burroughs

1 month ago | ionanalytics.com | Tim Burroughs |Edith Leung

Private equity investors see carve-outs as one of the biggest opportunities in Asia Pacific, despite patchy returns for this deal type, according to Bain & Company. More than 40% of respondents in a survey accompanying Bain & Co’s Asia Pacific Private Equity Report 2025 identified carve-outs as an interesting investment opportunity, ahead of sponsor-to-sponsor deals and take-privates. Companies with no prior sponsor involvement are seen as most attractive.

1 month ago | ionanalytics.com | Tim Burroughs |Edith Leung

India-focused ChrysCapital Partners has reached a first close of USD 1.4bn on its 10th private equity fund, according to three sources familiar with the situation. The first close took place earlier in March and the institutional hard cap has been set at USD 2bn, the sources added. Including the GP commitment, the final total is likely to be nearly USD 2.2bn. The fund is oversubscribed, and the fundraising process is expected to conclude towards the end of 2Q25, one of the sources said.

1 month ago | ionanalytics.com | Tim Burroughs |Edith Leung

Amit Gupta, one of TPG NewQuest’s four founding partners, will depart in June 2026 as part of a broader ongoing transition at the Asia-focused secondaries specialist that also includes several promotions and assorted new hires. LPs were recently informed that Gupta, who oversees investment activities in India and Southeast Asia, would make a staged exit over an approximately 16-month period, according to two sources familiar with the situation.

2 months ago | ionanalytics.com | Tim Burroughs |Edith Leung

Jean Eric Salata is Asia chairperson of EQT [STO:EQT] and head of EQT Private Capital Asia. Within private equity, the firm pursues mid-market and large-cap strategies, targeting buyouts of USD 50m-USD 300m and USD 300m to USD 3bn-plus. EQT recently announced that it expected to reach a first close on its ninth Asia large-cap buyout fund in the first half of 2025 at near the overall target of USD 12.5bn. Q: How do you address macro and geopolitical instability in investment decisions?

2 months ago | ionanalytics.com | Tim Burroughs |Edith Leung

News (Intelligence) • Big pharma is diversifying supply chains because of Biosecure Act concerns • Investment has shifted to India in expectation of API, CDMO expansion • Gaps must be filled in the ecosystem if India is to replicate China’s trajectory When WuXi AppTec [HKG:2359] agreed to divest the US and UK operations of its cell and gene therapy unit to New York-based healthcare investor Altaris in December, it was widely interpreted as a pre-emptive response to an impending regulatory...